MedTrace Logo

Ruxolitinib for Premalignant Breast Disease

NCT02928978 · Status: COMPLETED · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 84

Last updated 2026-04-13

No results posted yet for this study

Summary

This study is evaluating how ruxolitinib affects premalignant breast cells. One half of the study participants will receive ruxolitinib for approximately 15 days, and the other half will receive a placebo (sugar pill) for approximately 15 days. Once study participants have completed their ruxolitinib or placebo, participants will undergo surgery to remove the premalignant breast tissue.

Conditions

  • Ductal Carcinoma In Situ
  • Atypical Lobular Hyperplasia
  • Atypical Ductal Hyperplasia
  • Lobular Carcinoma In Situ

Interventions

DRUG

Ruxolitinib

tablet (taken by mouth)

DRUG

Placebo (for Ruxolitinib)

tablet (taken by mouth)

Sponsors & Collaborators

  • Incyte Corporation

    collaborator INDUSTRY

  • Translational Breast Cancer Research Consortium

    collaborator OTHER

  • Julie Nangia

    lead OTHER

Principal Investigators

  • Julie Nangia, M.D. · Baylor College of Medicine

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
TRIPLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2018-05-13
Primary Completion
2024-08-29
Completion
2024-09-18
FDA Drug
Yes

Countries

  • United States

Study Locations

More Related Trials

Entities

Drugs
Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT02928978 on ClinicalTrials.gov